tiprankstipranks
Advertisement
Advertisement

DNA X, Inc. delays 2025 annual filing

Story Highlights
  • DNA X, Inc. delays its 2025 Form 10-K (Yearly Report) mainly due to complexities from acquiring the DNA X trading platform.
  • The company expects to file within the fifteen-day grace period and does not foresee significant changes in operating results.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
DNA X, Inc. delays 2025 annual filing

Sonim Technologies ( (SONM) ) has released a notification of late filing.

Claim 55% Off TipRanks

DNA X, Inc., formerly Sonim Technologies Inc., has filed a Form 12b-25 to notify investors of a delay in submitting its Form 10-K (Yearly Report) for the financial year ended December 31, 2025. The late filing specifically concerns the company’s annual Form 10-K (Yearly Report), which is required under U.S. securities rules for listed firms.

The company cites its recent acquisition of the DNA X trading platform, completed in the fourth quarter of 2025, as the main reason for the delay. Management says the integration and compilation of the necessary financial and operational information from this deal have made it impractical to finalize the annual report on time without incurring unreasonable effort or expense.

DNA X, Inc. has stated that it expects to file the Form 10-K (Yearly Report) within the standard fifteen-calendar-day grace period allowed after the original deadline. Investors should therefore anticipate the annual filing to appear in early to mid-April 2026, assuming no additional complications arise in the audit or reporting process.

The company does not anticipate any significant change in results of operations compared with the prior fiscal year, according to the answers provided in the notification. That means management is not signaling any major earnings surprises at this time, though the usual forward-looking statement caveats apply and actual results could still differ once the Form 10-K (Yearly Report) is filed.

DNA X, Inc. also confirms that all other periodic reports required over the past 12 months have been filed on time, suggesting no broader pattern of reporting non-compliance. The notification is signed on behalf of the company by Chief Financial Officer Clay Crolius, underscoring management’s commitment to complete the audit, finalize the Form 10-K (Yearly Report), and maintain ongoing SEC reporting compliance.

The most recent analyst rating on (SONM) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Sonim Technologies stock, see the SONM Stock Forecast page.

Spark’s Take on SONM Stock

According to Spark, TipRanks’ AI Analyst, SONM is a Neutral.

The score is held down primarily by weak financial performance—heavy losses, substantial cash burn, and negative equity—despite a sharp revenue rebound. Technicals show mixed trend conditions with overbought momentum, while corporate events provide some support via balance-sheet simplification and potential Nasdaq compliance improvements; valuation is constrained by negative earnings.

To see Spark’s full report on SONM stock, click here.

More about Sonim Technologies

Average Trading Volume: 64,783

Technical Sentiment Signal: Sell

Current Market Cap: $6M

See more data about SONM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1